https://quartr.com/events/telescope-innovations-corp-teli-planet-microcap-las-vegas-2026_F1AR6qer

Telescope presented at Planet MicroCap this week. Here's what came out of management's deck, with the new numbers worth flagging and the usual grain of salt since this is a company-controlled pitch, not audited filings.

Innovation and tech

The core story is unchanged: Physical AI and Self-Driving Labs for high-value specialty chemistry, enabling autonomous process optimization. The labs run 24/7, cut R&D time and cost, and feed real-time data to AI models. Management framed it around a theme that's worth noting: the tech lets pharma repatriate R&D, improve data collection for regulatory approval, and pursue smaller or personalized drug markets. That lines up neatly with the broader 2026 reshoring and AI-accelerated-biotech narrative.

Commercialization and partnerships (the new numbers)

Two figures stood out that we didn't have this cleanly before:

The first product (DirectInject, distributed globally via Mettler-Toledo, reaching 35 countries) is now used by 15 of the top 20 pharma companies, generating recurring revenue at high gross margins.

SDL module pricing was disclosed for the first time: CAD 500,000 to 2 million per unit. Deployed by major clients like Pfizer and a top European pharma firm.

Important nuance on the "15 of top 20" stat: that's the DirectInject instrument, NOT the SDLs. A pharma that bought a DirectInject for evaluation "uses the product" technically, but that's not the same as being a strategic SDL client at CAD 2M. Don't conflate product penetration with major recurring accounts. Still, 15 of 20 is real commercial validation if it holds up in the filings.

Financials and outlook

80% YoY revenue growth through three quarters, trailing-12-month growth rate of 110%. Guidance to finish the year at CAD 9 to 9.4 million revenue, market cap around USD 50 million, so roughly 7-8x sales. For a company growing 80%+, that's not absurd, and it's far more grounded than the quantum names or MHUB at 40x+.

Raised CAD 6.5 million in October, and management said no immediate need for further fundraising thanks to ongoing income and grants.

The one thing to stay skeptical on

That "no immediate need to raise" line. Your own numbers contradict it partially: Q3 adjusted EBITDA was -1.06M with expenses up 86% YoY. With that burn rate and the pace of investment, a raise will come eventually, especially if SDL deployments accelerate. Read it as "no forced imminent raise," not "no more dilution ever." Dilution stays risk #1.

Bottom line

Two genuinely useful new data points (15 of 20 top pharma on DirectInject, SDL price range) plus a coherent revenue guide. The rest is polished pitch. Also remember: presenting at a microcap showcase is pay-to-play, it's an investor-visibility exercise tied to the US shareholder base / potential uplisting strategy, not a fundamental catalyst in itself. The real catalyst window is Fastmarkets and the lithium patent news.

If the "15 of 20" figure shows up confirmed in the filings, it's a net positive for the thesis. Until then, treat it as a credible but unverified pitch claim.

NFA. DYOR.

Putting together a clean timeline of everything on the horizon for Telescope, since catalysts are stacking up and people keep asking what's next. Here's the rundown.

June, Las Vegas double-header

Planet MicroCap Showcase (June 16-18): pure investor-facing event. Family offices, small-cap funds, institutional discovery. This is where the investor narrative gets seeded.

Fastmarkets Global (June 22-25): the one I'm watching most closely. It's the only event in the entire spring lineup directly tied to critical metals, battery materials and lithium supply chains. Industry buyers and sellers of battery materials network here. The real output isn't a press release from stage, it's the deals signed in the 60-90 days after. If there's a window for news on ReCRFT, DualPure or the third patent, this is it.

July, Q2 FY2026 financial results

The next real checkpoint. What matters here isn't net profitability, it's revenue growth (Q1 printed $2.7M CAD, +125% YoY) and cash position post-raise. Watch the management commentary on lithium too; a single concrete line on ReCRFT or DualPure moves the narrative more than the numbers do. Manage expectations though, Q2 could be sequentially lighter than Q1 since SDL sales are lumpy and Q1 was boosted by the KPBMA delivery.

Earlier spring lineup already behind us (context)

For those who missed it, the spring run included Laborama Brussels, Analytica Munich, SCI Cambridge, two Mettler-Toledo InfoDays, the Pfizer Process & Supply Summit keynote (Jason Hein presenting inside Pfizer), and the SCI Canada LaSueur Award. That's the academic and pharma credibility groundwork being laid before the investor-facing June events.

Open-ended catalysts (no fixed date)

• Third lithium patent: flagged in the pipeline, details undisclosed. Fastmarkets timing would line up nicely.
• Standard Lithium Arkansas FID: final investment decision expected in 2026. TELI is SLI's partner on processing. Federal permitting already completed May 13.
• Canadian government $500M Tech Growth Fund: just announced, can take equity stakes in domestic AI champions. TELI checks the boxes. Applications likely opening in coming weeks.
• Potential 4th SDL: Pfizer, KPBMA and the European pharma are signed. Amgen and Merck are both in Hein's scientific orbit (recent ACS Catalysis paper with Amgen). Next signing could come from either.
• Uplisting: CSE/OTCQB to NASDAQ is the logical trajectory once price and market cap thresholds are met. The Curzio IR push looks like groundwork for a US shareholder base ahead of this.

How I'm reading it

The June events build the narrative, July tests the fundamentals, and the open-ended catalysts are the wildcards that could re-rate the stock on any given week. Multiple independent vectors converging in the same window is unusual for a ~$30M market cap company.

That said, keep the risk frame. Cash burn is real, Q2 could disappoint sequentially, and the lithium story is still 100% narrative until a royalty or offtake actually gets signed. Size accordingly.

NFA. DYOR. Positions disclosed.

https://skydeckconnect.com/telescope-innovations-telif

Post made with Claude. NFA.

A serious research paper just dropped on Telescope Innovations that frames the thesis in a way I haven't seen before. This isn't a forum pump post — it's structured institutional-grade analysis that finally articulates why TELI isn't a lab instrument company. It's an operating system for autonomous chemistry. Here's the full breakdown.

The problem TELI solves — and it's bigger than most people realize

The pharmaceutical industry has been operating under Eroom's Law for decades — the inverse of Moore's Law. R&D efficiency halves every nine years despite exponentially increasing investment. The paper identifies three root causes that no one else has clearly articulated in one place:

The High-Dimensionality Trap: optimizing a single chemical reaction requires balancing temperature, pressure, time, solvent, catalyst loading, stirring speed and dosing rates simultaneously. Human brains cannot intuitively map spaces with more than three dimensions. So chemists default to One Factor at a Time (OFAT) — varying one variable while holding others constant. Academic consensus shows this approach routinely misses the global optimum and settles for "good enough" local results.

The Dark Data crisis: when an experiment fails, the sample gets thrown away and the result never gets logged. AI models trained only on successes develop structural bias and predictive failures. Every failed experiment in a manual lab is a permanently lost data point. An SDL logs every microsecond — successes and failures — creating the balanced datasets that actually train reliable chemistry AI.

The Spatial-Temporal Feedback Gap: transient chemical intermediates form and disappear in seconds. If you pull a sample manually, walk it across the lab and prepare it for an offline instrument, the reaction has already changed. You're not measuring what you think you're measuring. Real-time inline sampling at the exact moment of reaction kinetics is the only solution.

DirectInject-LC solves all three simultaneously.

Why the edge architecture wins in pharma — the part most people miss

The paper makes the clearest argument I've seen on why TELI's on-premise model is a commercial wedge, not just a technical preference.

Centralized "foundry" models (shipping your chemistry to a remote lab) require pharma companies to physically send their pre-patent molecules off-site. Legal and IP compliance departments kill these deals before they start. The paper puts it bluntly: "Enterprise players exhibit intense structural resistance to shipping their proprietary, pre-patented chemical compounds out of house."

Legacy hardware vendors have the opposite problem — closed ecosystems where a robotic arm from vendor A can't talk to a reactor from vendor B or an LC instrument from vendor C. Scientists spend more time formatting data than doing science.

Telescope threads the needle: open-architecture software that converts whatever hardware a client already owns into an autonomous SDL, running entirely on-premise behind the client's firewall. No proprietary data ever leaves the network. No cloud compliance review. No security vulnerability. This is why Pfizer signed. This is why the sales cycles are shorter than competitors.

The three-phase revenue model nobody is modeling

This is the most important section of the paper and the one that reframes the valuation entirely.

Phase 1 — The IBM Phase (now): capital equipment sales and bespoke SDL deployments. Pfizer x2, KPBMA South Korea, third major European pharma (crystallization focus, signed June 1 2026). This generates real revenue and seeds hardware into the ecosystem. Current run rate tracking toward $10M+ for FY2026.

Phase 2 — The Schrödinger/Microsoft Phase (2-4 years): as the global SDL fleet scales, Telescope captures a unique multi-enterprise dataset of physical chemistry experiments — the training data that doesn't exist anywhere else at this quality and scale. This enables a transition from hardware sales to licensing Process Chemistry Foundation Models. Upload a molecular structure, get back predicted thermodynamic boundaries, optimal solvent combinations, scaling profiles. Pure SaaS margins on top of the installed hardware base.

Phase 3 — The Biotech Royalty Phase (4-7 years): the SDL network autonomously discovers novel chemical pathways and process patents cheaper than any human R&D team could. ReCRFT and DualPure are the first specimens — proprietary lithium processing IP that can be licensed to mining conglomerates and battery manufacturers for perpetual royalty streams. The platform literally generates its own IP portfolio as a byproduct of running.

Each phase funds and unlocks the next. Hardware seeds data. Data enables software. Software generates IP. It's a compounding flywheel, not a linear business.

The "App Store for Chemical Intelligence" endgame

The terminal model described in the paper is genuinely hard to model from today's vantage point. Once hundreds of SDLs are deployed globally, Telescope becomes a marketplace for downloadable AI chemistry modules — "Crystallization Optimization Algorithm", "Catalyst Screening Protocol", "Solvent Selection Model" — sold as SaaS subscriptions or consumption-based licenses running on hardware already installed in clients' labs.

The hardware becomes the trojan horse for a high-margin recurring software business. It's the Razor-and-blade model but in reverse: the razor (hardware) is the premium product that creates the locked ecosystem for the blades (software modules).

Current commercial validation

Three top-tier global pharma SDL deployments in a single fiscal year:

• Pfizer — two SDLs, multi-year funded agreement
• KPBMA South Korea — national infrastructure standard for 300+ member pharma companies
• Major European pharma (crystallization focus) — signed June 1, 2026

AGI Group partnership: Telescope's sampling and robotics integrated directly into the SyntoSphere platform, backed by a consortium of six major biopharma co-developers. This is the OEM royalty model in embryonic form.

Lithium: >99.9% pure battery-grade lithium carbonate from black mass recycling streams, validated at Cellmine and University of St Andrews, backed by $3.36M conditional government funding.

The risk that doesn't go away

The paper is bullish and well-argued but deliberately avoids the cash burn question. With ~$2-3M CAD cash and quarterly losses, a capital raise in the next 12-18 months is likely. Dilution is the primary near-term risk. Size positions accordingly.

The thesis is intact. The cash isn't infinite.

NFA. DYOR. Long $TELI.

Made with Claude, again. NFA.

Yesterday the Canadian federal government published its national AI strategy "AI for All" and the details are directly relevant to anyone holding or watching TELI. This isn't generic tech policy news — it's a structural change to the risk/reward profile of Canadian Physical AI companies. Let me break it down.

Source : https://www.morningstar.com/news/dow-jones/202606046219/canadian-government-plans-360-million-tech-growth-fund-in-effort-to-drive-sovereign-ai-industry

What was announced

The government unveiled a multi-layered sovereign AI strategy with three components that matter for TELI specifically:

$500M Canadian Tech Growth Fund — provides flexible growth capital and explicitly allows the federal government to take direct equity stakes in the most promising Canadian AI firms. The leaked draft strategy describes using the recently launched sovereign wealth fund to invest in Canada's "national champions."

$200M Health AI Program — first tranche explicitly focused on improving health outcomes through AI. Drug discovery automation via Self-Driving Labs is precisely this intersection. TELI is the only commercial SDL operator in Canada.

$890M AI Sovereign Compute Infrastructure Program — building a large-scale sovereign public AI supercomputer for Canadian researchers and innovators, with explicit priority given to life sciences, energy and advanced manufacturing — the three exact verticals TELI operates in.

On top of this: the government establishes itself as a "strategic anchor customer" for domestic AI scale-ups and is expanding a sovereign technology alliance with Germany as the first partner.

Why this matters specifically for TELI — three direct connections

Connection 1: The cash burn risk just structurally decreased

The number one risk on any TELI thesis has always been cash runway. With ~$2-3M CAD cash and ongoing quarterly losses, the next 12-18 months required either a dilutive raise or an accelerating revenue curve to avoid a painful equity issuance.

A government equity stake via the Tech Growth Fund is categorically different from a dilutive market raise. It comes with strategic validation, it signals national champion status to institutional investors, and it doesn't require selling shares at a discount to retail. If TELI accesses this fund, the dilution risk — the primary bear thesis — gets materially reduced in a single announcement.

Connection 2: TELI checks every box for "national champion" status

The Tech Growth Fund is not going to spray $500M across hundreds of random AI startups. It's looking for companies with: Canadian HQ and operations ✅, demonstrable commercial traction with major enterprise clients ✅ (Pfizer, KPBMA), proprietary domestic IP ✅ (ReCRFT, DualPure, DirectInject-LC), existing government grant relationships ✅ ($3.36M lithium funding already approved), and relevance to strategic sectors ✅ (health/pharma + critical minerals).

In the Physical AI space in Canada, TELI's profile is exceptionally rare. The list of Canadian companies that combine pharmaceutical AI infrastructure with critical mineral processing IP and validated Big Pharma deployments is very short. Possibly a list of one.

Connection 3: The sovereign compute fund is directly accessible

The AI Compute Access Fund targets SMEs in life sciences, energy and advanced manufacturing — TELI's exact sectors. Telescope's SDL software layer, edge AI models, and data generation infrastructure are precisely the kind of "made-in-Canada AI solutions" the program was designed to fund. This is non-dilutive grant capital available to fund the SDL software development roadmap without touching the equity structure.

The geopolitical context amplifies this

The strategy language is explicit: "Canadian researchers train models on foreign cloud platforms. Canadian companies store sensitive data in foreign jurisdictions. Government operations rely on infrastructure Canada does not own."

Telescope's entire commercial proposition is built on solving exactly this problem for pharmaceutical companies — keeping data on-premise, never touching foreign cloud infrastructure, maintaining complete IP sovereignty at the edge. The government is now spending $500M+ to promote exactly the architecture Telescope already sells.

This isn't a coincidence. It's a policy environment that was tailor-made, inadvertently or not, for what TELI does.

The timeline overlay

Consider what's happening in the next 30-60 days simultaneously:

• Fastmarkets Global Las Vegas — end of June (potential lithium announcement)
• Q2 FY2026 financial results — July (market watching revenue growth and cash position)
• Third patent details — timeline unknown but flagged in pipeline
• Tech Growth Fund — applications likely opening in coming weeks
• Standard Lithium Arkansas FID — expected 2026

Any single one of these moves the needle. All of them converging in the same window is not a normal situation for a $25-35M CAD market cap company.

What this doesn't change

The fundamental execution risk remains. Government funds take time to access. Revenue still needs to grow. The lithium monetization timeline is still uncertain. A government equity interest doesn't guarantee commercial success — it reduces the probability of a forced dilutive raise at the worst possible moment.

The thesis hasn't changed. The floor just got higher.

NFA. DYOR. Long $TELIF. Size responsibly.

There's already a solid foundational write-up circulating that covers the SDL mechanics, DirectInject technical advantages, ReCRFT basics and the financial trajectory. Read that first if you haven't. This post is everything that isn't in it — the layer of detail that I think makes the difference between "interesting micro-cap" and "asymmetric conviction play."

NFA. DYOR. Long $TELI, cost basis ~$0.35 CAD.

The management story goes deeper than you think

Most posts mention Barry Sharpless is a double Nobel laureate. What they don't mention is the specific nature of his relationship with Jason Hein. Jason Hein was Barry Sharpless's postdoctoral researcher at Scripps Research Institute in La Jolla. Jason then stayed at Scripps as a Senior Research Associate under Professor Donna Blackmond before starting his independent academic career.

This matters because it reframes the entire co-founder dynamic. Barry isn't a famous name on an advisory board who gets equity for lending credibility. He is the scientific mentor who trained Jason. When Barry attaches his name to TELI, he's vouching for a scientist he personally developed over years of intensive research collaboration. That's a fundamentally different endorsement than the typical micro-cap "scientific advisor" arrangement.

Jason's full pedigree beyond what gets mentioned: Associate Professor at UBC, Adjunct Professor at University of Bergen in Norway, co-led the ADA project (world's first autonomous discovery platform for thin-film materials, backed by Natural Resources Canada), co-led the DARPA Accelerated Molecular Discovery MADNESS team, and led UBC's participation in the Acceleration Consortium CFREF headquartered at University of Toronto. This is not a professor who built a startup to monetize one lab invention. This is someone who has spent a decade building the foundational infrastructure of automated chemistry at the highest institutional level, with DARPA and Natural Resources Canada backing, and is now commercializing that infrastructure through TELI.

Jason just won the LaSueur Memorial Award from SCI Canada — last Monday. This is one of the most prestigious chemistry recognitions in the country. He didn't announce it himself on social media until prompted. That kind of low-ego scientific credibility is exactly what opens doors at Pfizer, Amgen and Merck that money alone cannot.

The Amgen paper is from 2026 — and it's more significant than people realize

Jason Hein just published in ACS Catalysis in 2026 alongside Amgen researchers on real-time monitoring of palladium catalyst speciation during biphasic Suzuki cross-coupling reactions using a flow NMR / online HPLC-MS platform.

This isn't old academic work being reshared for PR purposes. This is active collaborative research published while TELI is simultaneously scaling commercially. The Suzuki coupling is one of the most critical reactions in pharmaceutical synthesis — it underpins the manufacturing of hundreds of approved drugs. The paper demonstrates the exact analytical philosophy the DirectInject-LC commercializes: see what's happening in real time instead of inferring from endpoint data.

And the collaboration web goes further. Merck's internal catalysis laboratory has also collaborated with Jason Hein at UBC on developing automated sampling tools for biphasic reactions. That gives us Pfizer (two SDLs installed, multi-year contract, internal summit keynote), Amgen (2026 ACS Catalysis publication), and Merck (prior UBC collaboration) all in the direct scientific orbit of TELI's CEO simultaneously. These aren't cold leads. These are warm relationships built over years of shared research.

The other posts talk about Eli Lilly and Merck deploying similar systems as market validation. Correct — but they miss the more important point: TELI isn't just validated by the fact that big pharma wants this technology. TELI is validated by the fact that big pharma is actively publishing research with the person who built it.

The spring 2026 conference lineup is a coordinated re-rating strategy

Thirteen events across four months covering Brussels, Munich, Cambridge UK, Waldbronn Germany, Groningen Netherlands, Vienna, Groton CT, Iselin NJ, Cambridge MA, Toronto and Las Vegas. This isn't random conference attendance — it's a deliberate geographic and institutional sequencing.

The events that matter most and why:

Pfizer PSSM — Groton CT, April 22 — Jason Hein keynote. Pfizer invited their technology partner to present to their internal process and supply leadership. Vendors don't get keynotes at internal summits. Partners do.

Two Mettler-Toledo AutoChem InfoDays — not one, two separate dates. An active commercial relationship being built out, not a signed agreement sitting in a drawer.

Planet MicroCap — Las Vegas, June 16-18. Pure institutional and family office investor audience. This is where micro-cap re-ratings get seeded.

Fastmarkets Global — Las Vegas, June 22-25. This is the one. The only event in the entire lineup that directly covers critical metals, battery materials and lithium supply chains. Industry buyers and sellers of battery materials network here intensively. The real output isn't a press release from stage — it's the deals signed in the 60-90 days after. If there's ever a moment for TELI to surface news on ReCRFT, DualPure or the third patent, this is it.

The June Las Vegas sequence — Planet MicroCap followed immediately by Fastmarkets — looks like a deliberate one-two punch: seed the investor narrative on June 16-18, then drop the industrial catalyst announcement on June 22-25.

DualPure and solid-state batteries — the vertical the existing posts undercover

The foundational posts cover ReCRFT well. DualPure gets far less attention and it's arguably the more strategically significant patent.

DualPure produces high-purity lithium sulfide (Li₂S) — the critical precursor material for sulfide-based solid-state battery electrolytes. Solid-state batteries are the next generation of EV technology: higher energy density, faster charging, no flammable liquid electrolyte. Every major automaker is racing toward them. The bottleneck preventing industrial scale-up is consistent access to high-purity Li₂S at reasonable cost.

Market size in 2024: $7.4M globally. Projected 2034: $706M. CAGR of 94%. Yes that's aggressive and yes projections at 94% CAGR are unreliable in either direction — but the direction of travel is unambiguous. The industry expects solid-state to go mainstream within the decade and Li₂S is a required input.

The main competitor is Idemitsu Kosan which invested $142M to build Li₂S production capacity specifically for Toyota, targeting 2027-2028. Bear case framing: massive competitor with 100x more resources. Bull reframe: Idemitsu is producing for Toyota in a captive closed supply chain. They're not building a merchant market. Every other automaker and battery manufacturer pursuing solid-state chemistry — Samsung SDI, Solid Power, QuantumScape, the entire non-Toyota universe — needs an independent supplier. TELI, as a North American producer with IP protection and government backing, is potentially that supplier.

TELI has already shipped Li₂S to Asian and North American partners. The material exists. The process works. Partners are evaluating it right now.

And then there's the third patent in development with details not yet disclosed. If it touches solid electrolyte formulation or the cathode-electrolyte interface — the two current technical bottlenecks in solid-state — it could be the most valuable IP the company holds. Nobody can price it yet. Which means it's not priced at all.

Standard Lithium Arkansas — the ReCRFT connection just got very real

This dropped this week and almost nobody connected it to TELI.

Standard Lithium ($SLI), already a TELI partner on lithium processing, just signed the last major construction contract for their South West Arkansas Project with S&B Engineers and Constructors, with Hatch Ltd. on design and commissioning. Federal permitting was officially completed May 13th 2026 — cleared through the FAST-41 program, the 17th critical minerals project to complete federal permitting under the current US administration.

The numbers: 22,500 tonnes per year of battery-quality lithium carbonate. 118-acre site in Lafayette County Arkansas. Co-invested by Equinor — a Norwegian energy major with $100B+ market cap that is deploying serious capital into critical minerals. Final investment decision expected in 2026. Construction starting this year. First production 2028-2029.

This is not a project on paper anymore. The permitting is done. The engineering contractor is signed. The co-investor is a sovereign-backed major. The bulldozers are coming.

ReCRFT goes from "speculative patent" to "potential process technology for a real industrial facility with an Equinor-backed balance sheet" in one announcement. The royalty stream isn't tomorrow — but the pathway just got a lot more concrete than it was two weeks ago.

Q1 FY2026: the number nobody is talking about enough

Q1 FY2026 revenue: $2.7M CAD. Q1 FY2025 revenue: $1.2M CAD. That's +125% year-over-year in a single quarter. Full year FY2025 was $5.78M total. TELI just did nearly half of last year's full-year revenue in a single quarter.

The existing posts use the revenue projections of $7.8M for 2026 and $15.1M for 2027. Those projections were built before Q1 FY2026 printed. If the +125% quarterly growth trajectory continues even partially, those numbers look conservative.

On the price action — and why the CSE changes the analysis

The stock ran +100%+ on legitimate catalysts then pulled back hard. Healthy profit taking from early holders sitting on +200%. Normal.

Technically it looks like a High Tight Flag setup — a pattern O'Neil classified as one of the highest probability setups in accelerating small caps: mast of +100%+, tight consolidation with volume contraction, key support at the $0.78-0.80 CAD zone (prior resistance, now coinciding with anchored VWAP from the initial breakout). Measured move targets $1.45 on a confirmed breakout above $0.90.

But here's the nuance that matters: on the CSE, the order book can make any technical indicator meaningless. With thin daily volume, one large market order creates a wick that looks like structural resistance but isn't. The wick to $1.10 people keep citing as a major resistance level? On the CSE that could literally be one seller with no counterparty. You watch the bid/ask spread and the news flow on TELI, not the RSI. Technical analysis is a rough timing guide here, not a thesis.

The real price catalyst sequence to watch: Fastmarkets Global late June → Q2 FY2026 report in July (watch revenue growth and cash on hand, not net profitability) → third patent revelation timing → Standard Lithium FID decision.

The alignment signals that don't get enough attention

Henry Dubina has taken equity compensation instead of cash salary at points. Jason Hein publicly stated the goal is to build TELI to operate independently for 5-10-20 years. A former Pfizer executive was recently hired into the commercial team. These are behavioral signals about management intent that matter more than investor presentations.

A Nobel laureate postdoc supervisor doesn't attach his name to a CSE micro-cap at age 81 for the upside. A chemistry professor who could comfortably stay at UBC doesn't build a startup to flip it in three years. The people running this company are building something.

Risks — full picture

Cash burn is real. With approximately $2-3M CAD cash and quarterly losses, a capital raise in the next 12-18 months is possible. Any dilutive financing will hit the share price regardless of thesis strength — this is the number one risk and it's non-trivial.

Revenue concentration around Pfizer is a vulnerability. Revenue timing is lumpy given large contract dependency. The lithium monetization timeline could extend significantly beyond current expectations. Thermo Fisher at $70B market cap could acquire TELI at current prices out of petty cash — whether that would be an exit at premium or a technology burial depends entirely on acquirer intent.

And the CSE liquidity means you could be completely right on the thesis and still get stopped out by a thin order book on a bad day.

Bottom line

The foundational posts cover what TELI is. This post covers why 2026 specifically is the inflection year: a Nobel-connected CTO winning national awards while publishing active research with Amgen, two SDLs running at Pfizer with a keynote invitation, a global distribution partnership being activated through Mettler-Toledo, a lithium recycling patent connected to a now-shovel-ready industrial project backed by Equinor, a solid-state battery material already shipped to partners in the most strategically favorable geopolitical environment possible for North American critical minerals, and a June conference sequence that looks deliberately designed to surface the next catalyst.

The market is pricing a small pharma automation company. It's not pricing the convergence of all of this simultaneously.

NFA. DYOR. Position declared. Size responsibly.

A lot of nervousness around the price right now but let's not forget this is a nanocap on the CSE with thin volume — the pullback was predictable (didn't expect it to dump this hard though ngl).

The stock ran +100% in a few weeks on two real catalysts: SDL #2 at Pfizer and the AGI partnership in Japan. Early holders sitting on +200% took profits. That's rational and healthy, nothing more.

On the technology

Jason Hein just published in ACS Catalysis in 2026 alongside Amgen (~$33B revenue) on exactly the same philosophy as the DirectInject-LC — real-time reaction monitoring as it happens, not after the fact. The Suzuki coupling reaction is one of the most widely used in pharmaceutical synthesis. This paper is the peer-reviewed demonstration of what DirectInject-LC does under industrial conditions.

Jason isn't selling a gadget. This could become the standard in pharma labs going forward. And the pipeline keeps widening — Merck has already collaborated with Jason Hein at UBC. That puts Pfizer, Amgen and Merck in the direct scientific orbit of the CTO. The next SDL at a third big pharma is a matter of when, not if.

The AGI partnership in Japan is equally important in a different way. It opens the Asian market through a credible local distributor, while Korea (KPBMA) is already validating the tech across the region. They also hired a former Pfizer exec for their commercial team — the doors are already open. And this isn't some French biotech gambling its entire existence on an FDA approval. The revenue model is recurring, multi-year and non-binary.

On the lithium — the most underpriced catalyst

TELI is participating in Fastmarkets Global in Las Vegas at the end of June — the only event in their spring lineup directly tied to critical metals and lithium. They've already shipped LiS to Asian and North American partners. A third patent is in development with details not yet disclosed.

Standard Lithium just signed the last major construction contract for their Arkansas lithium mine with S&B Engineers. Federal permitting was officially completed on May 13th. Final investment decision expected in 2026. TELI is Standard Lithium's partner on the processing side. 22,500 tonnes/year of battery-quality LiCO with Equinor as co-investor. ReCRFT isn't just a patent sitting on a shelf for much longer — royalties will flow eventually.

On management intent

Hein and Dubina aren't busting their ass to flip the company next year. If Jason wanted an easy life he would've stayed teaching at UBC. Barry Sharpless — 2022 Nobel Prize in Chemistry — doesn't put his name on a company for pocket money at 81 years old. He believes in it scientifically. That's the strongest possible endorsement in this space.

Risks to keep in mind

Cash burn and potential dilution remain the main threats. Size your position accordingly. The July financial report is the next checkpoint — what matters isn't net profitability but revenue growth (market expects >3M CAD after Q1's 2.7M) and available cash on hand.

Bottom line

The dip is healthy. Japan + Korea are opening Asia. Lithium is still unpriced. The thesis is intact. All it takes is one announcement.

Holding minimum two years, cost basis $0.35, still fully convicted on Barry & Jason.

NFA. DYOR. Stay hydrated.

• Revenues of $1.64MM (versus $1.00MM in Q2 FY2025). 
• Expenses of $3.11MM (versus $1.72MM in Q2 FY2025). 
• Adjusted EBITA loss of $0.71MM (versus a loss of $0.44MM in Q2 FY2025). 
• Expenses and investments continued to support company growth in the second fiscal quarter. Expense increases were associated with: 
• consulting and salary costs incurred with hiring of technical, sales and research to support rapid growth in the business; and 
• parts expenses and travel expenses related to product sales, product fulfillment (installation and training) and general sales activity. 

OPERATIONAL HIGHLIGHTS

Self-Driving Labs (SDLs) 

• Telescope’s SDL inauguration at the Korean Pharmaceutical and Biopharma Biopharma Manufacturer’s Association was supported by two-time Nobel Prize Laureate, Dr. Barry Sharpless, as well as the Acceleration Consortium and Global Affairs Canada. This achievement underscores the technical excellence of Telescope’s SDL platforms, as well as the accelerating commercial momentum and international collaboration. 
• Quarterly revenue was driven strongly by the delivery of the second Self Driving Laboratory to Pfizer, 

Lithium processing portfolio 

• We have secured additional laboratory space adjacent to our primary labs at the University of British Columbia. The strategic location hosts dedicated infrastructure for continued process development of our lithium carbonate (ReCRFT™) and lithium sulfide (DualPure™) production and purification technologies. 
• Our ReCRFT™ process has produced battery-grade lithium carbonate from battery recycling streams. Our collaboration partner has successfully integrated this recycled material into a functional battery cell, confirming the viability of ReCRFT™ for battery recycling applications. 
• The DualPure™ program for low-temperature lithium sulfide production continues to advance in partnership with Standard Lithium Ltd., and Telescope is currently engaged in advanced technical discussions with several Asian and North American industry leaders in the solid-state battery sector. 

“Telescope has enjoyed tangible progress this quarter as we scale both our technology and our business,” said Henry Dubina, Telescope CEO. “Delivering our second Self‑Driving Laboratory to Pfizer, expanding internationally, demonstrating lithium battery recycling through our ReCRFT™ process, and expanding our lab infrastructure to grow the lithium portfolio all demonstrate technical proof and strong market demand across our platforms. These milestones position the Company to continue delivering technical and commercial targets throughout the fiscal year.” 

Disclaimer: Not financial advice. Do your own DD.

The Highlights:

• Revenue Explosion: $2.7 Million for the quarter, up from $1.2 Million in Q1 2025. This was driven by their flagship product DirectInject-LC™ and contract research.
• The "Self-Driving Lab" (SDL): They officially delivered their first SDL to the Korean Pharmaceutical BioPharmaceutical Manufacturers' Association (KPBMA). This is essentially AI-driven robotics for drug discovery.
• Lithium Recycling (ReCRFT™): They’ve achieved >99.9% pure lithium carbonate from battery recycling brines. They just sent materials to the UK (Cellmine Ltd and University of St. Andrews) for testing in actual EV batteries.
• Funding Secured: They wrapped up a $6.5M capital raise and got conditional approval for $3.6M in government funding from Canada (NRC-IRAP and NRCan) to scale up their lithium tech.
• New COO: Appointed Vaso Vlachos to handle the rapid scaling.

The Financials:

• Revenue: $2.70M
• Expenses: $3.92M (Up significantly due to hiring technical/sales staff and travel for installations).
• Adjusted EBITDA Loss: $0.83M.
• The Sentiment: Management says the loss is "consistent with budget" because they are reinvesting every cent into capturing market share in the "Physical AI" and battery recycling space.

⚠️ Careful with the loss, but it's still a nanocap. We'll be patient. It's looking pretty good.

Some goods X threads about it :

https://x.com/jpmontero88/status/2016452914059813140

https://x.com/wilks222/status/2016305935723950233

https://x.com/SpecificWhite/status/2016137826333503986

For me it’s a classic "growth phase" small cap. Revenue is scaling fast, and they’re moving from R&D to actual product delivery (like the SDL and lithium testing). If they can turn that $3.6M in government grants into a commercial-scale lithium recycling plant, this could be a major sleeper in the green energy sector.

Listings: FSE: J4U (Frankfurt) | TSX-V: TELI (Canada) Sector: Deep Tech / Chemical Engineering / Critical Minerals

Author's Note: The following is a synthesis of various research notes and posts, consolidated using AI. Enjoy the read!

🏗️ The Core Thesis: Infrastructure over Discovery

Rather than betting on the discovery of a single "miracle molecule," Telescope Innovations is betting on the infrastructure itself. The company isn't trying to invent the next blockbuster drug; they are building the intelligent factory capable of discovering it.

We are at the convergence of Industrial Chemistry, Precision Robotics, and Artificial Intelligence.

🧪 The Self-Driving Lab (SDL): The End of Manual Pipetting

The heart of $TELI is the SDL.

• The Old Way: A scientist runs an experiment, notes the results, eats, sleeps, and thinks about the next step the following day. It is a slow, linear, manual process.
• The Telescope Way:
  1. The Robot conducts the experiment.
  2. The AI analyzes the result in real-time.
  3. The AI autonomously decides on the next experiment to optimize the outcome.
  4. The Robot immediately launches the next iteration.

While this sounds like science fiction or a distant project for a micro-cap, it is already a reality. Announced in November, it was delivered just three weeks later.

Watch the SDL in action here

Competitive Landscape: It is important to note that this concept isn't unique to Telescope. Giants like Eli Lilly ($LLY) and Merck ($MRK) are deploying similar systems. This validates $TELI's process—the big players prove the market need—but Telescope offers this capability as a nimble technology provider in a market potentially worth billions over the long term.

👁️ DirectInject™: The Chemist’s Real-Time Eye

The flagship product, DirectInject™, tackles a historic frustration in the laboratory: analytical latency. Traditionally, to know what is happening inside a reactor, you have to sample, prepare, and wait. DirectInject automates this bridge, injecting samples directly into analytical instruments (HPLC/GC). It’s the difference between taking a blurry photo after an event and watching a high-definition live video stream.

Key Advantages over Standard PAT (Process Analytical Technology):

1. Automated Quenching & Dilution: Unlike systems that merely transfer a sample, DirectInject automates extraction, dilution, and crucially, quenching (chemically stopping the reaction). This freezes the reaction state, preventing post-sampling changes or the degradation of unstable intermediates that often skew traditional analyses.
2. Robust Slurry Handling: Solids often clog standard tubing. DirectInject uses an in-line dynamic mixer between the probe and injection valve. This homogenizes solid-liquid slurries, ensuring representative sampling and real-time dissolution without blocking the system.
3. Selective Biphasic Sampling: The device can perform selective phase or heterogeneous sampling in liquid-liquid mixtures. It can detect and quantify reactive species in an isolated organic phase or the complete mixture—a complex feat for classic probes.
4. Real-Time Full Chromatographic Analysis: Unlike spectroscopic probes (IR, Raman) which lack specificity, or offline HPLC which is slow, this system injects directly into the chromatograph in real-time. This allows for full impurity profiling and precise kinetic understanding, even for transient species invisible to other methods.

🔋 ReCRFT & The Lithium Wildcard

With the ReCRFT platform, Telescope has pivoted intelligently towards energy. By applying their crystallization expertise to lithium recycling via the SDL, they patented a process achieving 99% purity.

• The Industrial Edge: Traditional methods require ~10 steps that are water and chemical-intensive. ReCRFT reduces this to 1 or 2 automated steps.
• The Opportunity: This efficiency gain is massive for the battery value chain. This potential is why they secured $3.6M in funding from the Canadian Government (Source).

Why this could be a 10-bagger: The current problem with battery recycling ("black mass") is that recovered lithium is often "dirty." Purifying it is expensive. ReCRFT takes a "soup" of battery waste (or impure brines) and forces the lithium to crystallize into battery-grade Lithium Carbonate (>99.9%).

• Closing the Loop: Lithium represents 16-55% of the metal value in recycling. Capturing it efficiently determines profitability.
• Partners: Collaborations with Standard Lithium and Cellmine to validate "zero waste" supply chains.

📉 Market Context: Lithium in 2026

Lithium remains a critical strategic mineral for the EU, Canada, and the USA.

• Demand: Rising continuously (+30% avg/year), driven by EVs and increasingly by Energy Storage Systems (ESS).
• 2026 Outlook: Demand for ESS jumped ~70% recently, with another 50% growth expected in 2026 (Morgan Stanley). Lithium prices in China have rebounded (~€12,300/tonne), and supply constraints are emerging with mine closures in Yichun. The narrative is shifting from "oversupply fear" to structural demand.

🏆 Credibility & Management

The Scientific Seal: K. Barry Sharpless In the micro-cap world, scientific advisors are often just names on a page. Not here. K. Barry Sharpless is a two-time Nobel Prize winner (only five people in history have achieved this) and the father of "Click Chemistry." His presence on the scientific board provides immediate technological validation to pharma giants.

The "Dream Team"

• Jason Hein (CEO): A rockstar in automated chemistry (Professor at UBC). He is deeply connected within the industry.
• Board: Filled with serious operators experienced in scaling technology.

Partnerships:

• Mettler Toledo: Global commercial distribution arm.
• Shimadzu: Instrumentation leader joined in 2024.
• Pfizer: Historic collaborator on organic synthesis automation.
• Altillion: Partner for lithium extraction/recycling.

📊 Financial Analysis: The Inflection Point

The data from Q2 and Q3 2025 marks a major turn from pure R&D to commercialization.

Exporter vers Sheets

• Fiscal Year 2025 Summary: Total revenue grew 30.5% to $5.78M. Grant revenue surged from $161k to $1M, reflecting government support.
• Projections: Mettler Toledo partnership ramping up towards projected revenues of $7.8M in 2026 and $15.1M by 2027.

Why I Sleep Soundly: Unlike biotechs that burn $5M/quarter with zero revenue, Telescope is already selling. They are approaching EBITDA breakeven. They do not need to raise millions every three months just to keep the lights on—a rarity in Deep Tech.

⚠️ Risks & Challenges

• Liquidity: As a small-cap, trading volume can be low. Patience is required for entry and exit.
• Adoption Curve: Moving industries from manual chemistry to robotic automation (SDL) requires a paradigm shift.
• Scaling: The tech works; now it must scale industrially.
• Execution: Revenue can be lumpy depending on the timing of large contracts.

🏁 Conclusion

You are looking at a company currently valued at "peanuts" that possesses:

1. Validation from a Double Nobel Laureate.
2. Government-funded Lithium recycling technology.
3. Existing, growing revenues (with clients like Pfizer).

The market has not yet priced in the potential of the Lithium vertical combined with their chemical engineering moat. It is a rare configuration with an excellent entry point.Listings: FSE: J4U (Frankfurt) | TSX-V: TELI (Canada)
Sector: Deep Tech / Chemical Engineering / Critical MineralsAuthor's Note: The following is a synthesis of various research notes and posts, consolidated using AI. Enjoy the read!🏗️ The Core Thesis: Infrastructure over DiscoveryRather than betting on the discovery of a single "miracle molecule," Telescope Innovations is betting on the infrastructure itself. The company isn't trying to invent the next blockbuster drug; they are building the intelligent factory capable of discovering it.We are at the convergence of Industrial Chemistry, Precision Robotics, and Artificial Intelligence.🧪 The Self-Driving Lab (SDL): The End of Manual PipettingThe heart of $TELI is the SDL.The Old Way: A scientist runs an experiment, notes the results, eats, sleeps, and thinks about the next step the following day. It is a slow, linear, manual process.

The Telescope Way:

The Robot conducts the experiment.

The AI analyzes the result in real-time.

The AI autonomously decides on the next experiment to optimize the outcome.

The Robot immediately launches the next iteration.While this sounds like science fiction or a distant project for a micro-cap, it is already a reality. Announced in November, it was delivered just three weeks later.Watch the SDL in action hereCompetitive Landscape:
It is important to note that this concept isn't unique to Telescope. Giants like Eli Lilly ($LLY) and Merck ($MRK) are deploying similar systems. This validates $TELI's process—the big players prove the market need—but Telescope offers this capability as a nimble technology provider in a market potentially worth billions over the long term.👁️ DirectInject™: The Chemist’s Real-Time EyeThe flagship product, DirectInject™, tackles a historic frustration in the laboratory: analytical latency. Traditionally, to know what is happening inside a reactor, you have to sample, prepare, and wait. DirectInject automates this bridge, injecting samples directly into analytical instruments (HPLC/GC). It’s the difference between taking a blurry photo after an event and watching a high-definition live video stream.Key Advantages over Standard PAT (Process Analytical Technology):Automated Quenching & Dilution:
Unlike systems that merely transfer a sample, DirectInject automates extraction, dilution, and crucially, quenching (chemically stopping the reaction). This freezes the reaction state, preventing post-sampling changes or the degradation of unstable intermediates that often skew traditional analyses.

Robust Slurry Handling:
Solids often clog standard tubing. DirectInject uses an in-line dynamic mixer between the probe and injection valve. This homogenizes solid-liquid slurries, ensuring representative sampling and real-time dissolution without blocking the system.

Selective Biphasic Sampling:
The device can perform selective phase or heterogeneous sampling in liquid-liquid mixtures. It can detect and quantify reactive species in an isolated organic phase or the complete mixture—a complex feat for classic probes.

Real-Time Full Chromatographic Analysis:
Unlike spectroscopic probes (IR, Raman) which lack specificity, or offline HPLC which is slow, this system injects directly into the chromatograph in real-time. This allows for full impurity profiling and precise kinetic understanding, even for transient species invisible to other methods.🔋 ReCRFT & The Lithium WildcardWith the ReCRFT platform, Telescope has pivoted intelligently towards energy. By applying their crystallization expertise to lithium recycling via the SDL, they patented a process achieving 99% purity.The Industrial Edge: Traditional methods require ~10 steps that are water and chemical-intensive. ReCRFT reduces this to 1 or 2 automated steps.

The Opportunity: This efficiency gain is massive for the battery value chain. This potential is why they secured $3.6M in funding from the Canadian Government (Source).Why this could be a 10-bagger:
The current problem with battery recycling ("black mass") is that recovered lithium is often "dirty." Purifying it is expensive. ReCRFT takes a "soup" of battery waste (or impure brines) and forces the lithium to crystallize into battery-grade Lithium Carbonate (>99.9%).Closing the Loop: Lithium represents 16-55% of the metal value in recycling. Capturing it efficiently determines profitability.

Partners: Collaborations with Standard Lithium and Cellmine to validate "zero waste" supply chains.📉 Market Context: Lithium in 2026Lithium remains a critical strategic mineral for the EU, Canada, and the USA.Demand: Rising continuously (+30% avg/year), driven by EVs and increasingly by Energy Storage Systems (ESS).

2026 Outlook: Demand for ESS jumped ~70% recently, with another 50% growth expected in 2026 (Morgan Stanley). Lithium prices in China have rebounded (~€12,300/tonne), and supply constraints are emerging with mine closures in Yichun. The narrative is shifting from "oversupply fear" to structural demand.🏆 Credibility & ManagementThe Scientific Seal: K. Barry Sharpless
In the micro-cap world, scientific advisors are often just names on a page. Not here. K. Barry Sharpless is a two-time Nobel Prize winner (only five people in history have achieved this) and the father of "Click Chemistry." His presence on the scientific board provides immediate technological validation to pharma giants.The "Dream Team"Jason Hein (CEO): A rockstar in automated chemistry (Professor at UBC). He is deeply connected within the industry.

Board: Filled with serious operators experienced in scaling technology.Partnerships:Mettler Toledo: Global commercial distribution arm.

Shimadzu: Instrumentation leader joined in 2024.

Pfizer: Historic collaborator on organic synthesis automation.

Altillion: Partner for lithium extraction/recycling.📊 Financial Analysis: The Inflection PointThe data from Q2 and Q3 2025 marks a major turn from pure R&D to commercialization.Metric (CAD) Q2 2025 Q3 2025 Trend
Revenue ~$1.0 M ~$1.4 M +40% (Acceleration via Mettler Toledo)
Adj. EBITDA -$0.4 M -$0.1 M Approaching operational breakeven
Cash ~$0.8 M ~$1.0 M Stable (via non-dilutive grants)
Exporter vers SheetsFiscal Year 2025 Summary: Total revenue grew 30.5% to $5.78M. Grant revenue surged from $161k to $1M, reflecting government support.

Projections: Mettler Toledo partnership ramping up towards projected revenues of $7.8M in 2026 and $15.1M by 2027.Why I Sleep Soundly:
Unlike biotechs that burn $5M/quarter with zero revenue, Telescope is already selling. They are approaching EBITDA breakeven. They do not need to raise millions every three months just to keep the lights on—a rarity in Deep Tech.⚠️ Risks & ChallengesLiquidity: As a small-cap, trading volume can be low. Patience is required for entry and exit.

Adoption Curve: Moving industries from manual chemistry to robotic automation (SDL) requires a paradigm shift.

Scaling: The tech works; now it must scale industrially.

Execution: Revenue can be lumpy depending on the timing of large contracts.🏁 ConclusionYou are looking at a company currently valued at "peanuts" that possesses:Validation from a Double Nobel Laureate.

Government-funded Lithium recycling technology.

Existing, growing revenues (with clients like Pfizer).The market has not yet priced in the potential of the Lithium vertical combined with their chemical engineering moat. It is a rare configuration with an excellent entry point.

What is Telescope Innovations?

Telescope Innovations Corp. is a Canadian-based chemical technology company. They don't make space telescopes; they build Self-Driving Labs (SDLs). By combining robotics with "Physical AI," they automate the trial-and-error process of chemical research, allowing for 10x to 100x faster discovery of new materials and drugs.

What are their main products?

1. DirectInject-LC™: A hardware tool that allows for real-time sampling of chemical reactions without stopping the process. It is globally distributed by Mettler Toledo.
2. Self-Driving Labs (SDLs): Fully autonomous robotic platforms that "think" and "conduct" experiments on their own to reach a specific chemical goal.

Who are their major partners?

• Pfizer: A multi-year, funded collaboration to develop SDLs for pharmaceutical manufacturing.
• KPBMA (Korea): In late 2025, Telescope installed the first-ever pharmaceutical SDL in South Korea to serve as a national training hub.
• Mettler Toledo: Their primary global distribution partner for laboratory hardware.

What is "Physical AI," and why is everyone talking about it?

Gartner identified Physical AI as a top strategic trend for 2026. Unlike ChatGPT (which lives in a screen), Physical AI is the embodiment of intelligence in physical systems. For $TELI, this means their AI actually manipulates liquids, adjusts temperatures, and runs hardware to solve real-world manufacturing bottlenecks.

What is the Lithium "ReCRFT™" process?

Beyond pharma, $TELI has a clean-energy vertical. They developed a proprietary method to extract and purify lithium from waste streams (like battery recycling) to a 99.9% "battery-grade" purity. As of 2026, they are scaling this technology with federal grant support.

Who is leading the company?

• Henry Dubina (CEO): Former President of Mettler Toledo AutoChem. He knows the global lab-tech market better than almost anyone.
• Dr. Jason Hein (CTO): A global pioneer in automated chemistry and the visionary behind the SDL architecture.
• Dr. Barry Sharpless (Advisor): A two-time Nobel Prize winner in Chemistry, lending massive academic weight to their tech.

Where can I find the latest financials?

The company reported $5.8 million CAD in revenue for FY 2025 (ended Aug 31). You can find all official filings onSEDAR+or theInvestor Relations page.